ANTIBACTERIAL IN-VITRO ACTIVITY OF PIPERACILLIN-TAZOBACTAM IN COMBINATION WITH NETILMICIN OR AMIKACIN AGAINST AMOXICILLIN-RESISTANT STRAINS OF ENTEROBACTERIACEAE

被引:0
|
作者
DUEZ, JM
SIEBOR, E
PECHINOT, A
CORDIN, X
CHAMARDNEUWIRTH, C
KAZMIERCZAK, A
机构
来源
PATHOLOGIE BIOLOGIE | 1995年 / 43卷 / 03期
关键词
IN VITRO ACTIVITY; PIPERACILLIN TAZOBACTAM; AMINOGLYCOSIDE; ANTIBIOTIC COMBINATION; ENTEROBACTERIACEAE;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The antibacterial in vitro activity of piperacillin and tazobactam (in a concentration ratio of 8/1) was studied in combination with netilmicin or amikacin by a microtiter checkerboard assay against 162 strains of Enterobacteriaceae. These strains were selected for their resistance pattern to beta-lactam antibiotics and their beta-lactamases were characterized by the mean of isoelectric focusing in comparison with reference strains. A comparison of the MICs of piperacillin, alone and in combination, assessed the efficacy of tazobactam as beta-lactamase inhibitor, particularly when a TEM-1 beta-lactamase was produced. When the strains were sensitive to the aminoglycosides(lll netilmicin-sensitive ones and 131 amikacin-sensitive ones), we observed 55 % of synergistic effects and 45 % of additions with the combinations piperacillin-tazobactam-netilmicin or amikacin. A synergistic effect was usually encountered with P. mirabilis, P. vulgaris, M, morganii and with the strains off. coli, E. cloacae and S. marcescens which produced a cephalosporinase only. Among the 51 strains that were intermediate or resistant to netilmicin, 8 ones were inhibited by piperacillin-tazobactam-netilmicin at therapeutic levels (3 synergisms, 5 additions). Among the 31 strains that were intermediate or resistant to amikacin, 24 ones (18 synergisms, 6 additions) were inhibited by piperacillin-tazobactam-amikacin at therapeutic concentrations. In most of the cases, the combination of piperacillin-tazobactam with an aminoglycoside enhanced the antibacterial activity of these agents by decreasing the concentrations necessary to inhibit the strains.
引用
收藏
页码:208 / 214
页数:7
相关论文
共 50 条
  • [21] In Vitro Activities of Clindamycin, Imipenem, Metronidazole, and Piperacillin-Tazobactam against Susceptible and Resistant Isolates of Bacteroides fragilis Evaluated by Kill Kinetics
    Schaumann, Reiner
    Funke, Matthias
    Janssen, Eva
    Rodloff, Arne C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) : 3413 - 3416
  • [22] In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units
    Bonfiglio, G
    Laksai, Y
    Franceschini, N
    Perilli, M
    Segatore, B
    Bianchi, C
    Stefani, S
    Amicosante, G
    Nicoletti, G
    CHEMOTHERAPY, 1998, 44 (05) : 305 - 312
  • [23] IN-VITRO ACTIVITY OF IMIPENEM AND AMIKACIN COMBINATIONS AGAINST RESISTANT PSEUDOMONAS-AERUGINOSA
    FUJITA, J
    NEGAYAMA, K
    TAKIGAWA, K
    YAMAGISHI, Y
    YAMAJI, Y
    KAWANISHI, K
    TAKAHARA, J
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (06) : 1007 - 1009
  • [24] In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii
    Hogg, GM
    Barr, JG
    Webb, CH
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (04) : 494 - 495
  • [25] COMPARATIVE IN-VITRO ACTIVITY OF PIPERACILLIN TAZOBACTAM AGAINST RECENT CLINICAL ISOLATES, A DUTCH NATIONAL MULTICENTER STUDY
    STOBBERINGH, EE
    MACLAREN, DM
    SCHMITZ, PIM
    DIRKSGO, SIS
    DANKERT, J
    LIGTVOET, EEJ
    LICHTENDAHLBERNARDS, AT
    HORREVORTS, AM
    THEWESSEN, EAPM
    BANFFER, JRJ
    WAGENVOORT, JHT
    HENDRIKS, WDH
    BRIMICOMBE, RW
    LIM, BT
    VISSER, MR
    VANKLINGEREN, B
    VANKREGTEN, E
    DEJONG, J
    SCHREUDER, H
    SABBE, LJM
    WINTERMANS, RGF
    DIEPERSLOOT, RJA
    SONDERKAMP, HJA
    VANDIJKE, BF
    FABIUS, GTJ
    DAVIES, BI
    HOOGKAMPKORSTANJE, JAA
    DEJONG, A
    SEVERIN, WPJ
    DEGENER, JE
    MANSON, WL
    VERBRUGH, H
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 34 (05) : 777 - 783
  • [26] Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model
    Islam, Kamrul
    Sime, Fekade B.
    Wallis, Steven C.
    Bauer, Michelle J.
    Naicker, Saiyuri
    Won, Hayoung
    Zowawi, Hosam M.
    Abu Choudhury, Md
    Shirin, Tahmina
    Habib, Zakir H.
    Harris, Patrick N. A.
    Flora, Meerjady S.
    Roberts, Jason A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [27] Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses
    Stearne, LET
    van Boxtel, D
    Lemmens, N
    Goessens, WHF
    Mouton, JW
    Gyssens, IC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) : 1688 - 1698
  • [28] In Vitro Antibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases
    Levasseur, Premavathy
    Girard, Anne-Marie
    Miossec, Christine
    Pace, John
    Coleman, Ken
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (04) : 1931 - 1934
  • [29] Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin
    Kulengowski, Brandon
    Clark, Justin A.
    Burgess, David S.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 93 (04) : 372 - 375
  • [30] Evaluation of Vancomycin in Combination with Piperacillin-Tazobactam or Oxacillin against Clinical Methicillin-Resistant Staphylococcus aureus Isolates and Vancomycin-Intermediate S. aureus Isolates In Vitro
    Dilworth, Thomas J.
    Sliwinski, Jora
    Ryan, Keenan
    Dodd, Monique
    Mercier, Renee-Claude
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) : 1028 - 1033